---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-008536"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T15:34:37.737276+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA schedules advisory committee meeting for Geron's imetelstat NDA on March 14, 2024

## Summary
- FDA's Oncologic Drugs Advisory Committee will review imetelstat for transfusion-dependent anemia in lower-risk MDS on March 14, 2024.
- Meeting is scheduled from 9:30 a.m. to 3:00 p.m. ET, and will be open to the public.
- PDUFA action date for the NDA remains June 16, 2024.
- Federal Register notice published January 30, 2024 provides details of the advisory committee meeting.

## SEC filing metadata
- accession: 0000950170-24-008536
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000095017024008536/0000950170-24-008536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000095017024008536/gern-20240130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-008536
- JSON: https://secwatch.observer/filing/0000950170-24-008536.json
- Plain text: https://secwatch.observer/filing/0000950170-24-008536.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.